You are not currently logged in.
Access JSTOR through your library or other institution:
A New Generation of β-Lactam Antibiotics: Anticipating Future Developments and Needs
George Gee Jackson
Reviews of Infectious Diseases
Vol. 4, Supplement. Moxalactam International Symposium (Nov. - Dec., 1982), pp. S720-S726
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4452964
Page Count: 7
Preview not available
The development of a drug with the properties of moxalactam creates both a new class of β-lactam antibiotics and potentially a new era in chemotherapy. The specific activity (antibacterial effect/mg), stability against enzymatic degradation, and pharmacologic advantages of moxalactam provide new promise for the treatment of some infections and for moving forward our understanding of bacterial properties and the processes of infection. Such conditions offer numerous opportunities for development of new knowledge and improved practices in antimicrobial therapy. As the quality of antibiotics is improved through modification by chemical synthesis, some biologic and clinical needs shift. Experience provides a basis for anticipation and recognition of some of the conditions that are most likely to occur. Physicians should be alert to these possibilities and to their opportunity for making observations that will establish the optimal use of moxalactam, the first of a new generation of β-lactam antibiotics.
Reviews of Infectious Diseases © 1982 Oxford University Press